Aurobindo Pharma
- Revenue₹245.6 BFY, 2021
- Market Capitalization₹329.6 B2022-05-13
OverviewSuggest Edit
Aurobindo Pharma, a pharmaceutical company, manufactures and sells generic medicines to public and private health sectors in South Africa. The company’s product portfolio includes central nervous system, cardiovascular, pain, respiratory, anti-retroviral (for state tenders), metabolic, and anti-infective products. It markets and sells its products to health care professionals.
A well integrated pharma company, Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations. Our customers include premium multi-national companies.. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India.
| Type | Public | |
| Founded | 1986 | |
| HQ | Hyderabad, IN | Map |
| Website | aurobindo.com | |
| Employee Ratings |
Recent NewsAll News
Key People/Management at Aurobindo Pharma
M. Sivakumaran
K. Ragunathan
M. Madan Mohan Reddy
M. Sitarama Murthy
Avnit Bimal Singh
Savita Mahajan
Aurobindo Pharma Office Locations
Aurobindo Pharma Financials and Metrics
Aurobindo Pharma Revenue
| INR | |
|---|---|
Revenue (Q3, 2022) | 59.9b |
Gross profit (Q3, 2022) | 33.0b |
Net income (Q3, 2022) | 6.0b |
EBITDA (Q3, 2022) | 10.5b |
EBIT (Q3, 2022) | 7.9b |
Market capitalization (13-May-2022) | 329.6b |
Closing stock price (13-May-2022) | 562.5 |
EV | 329.6b |
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 162.0b | 192.3b | 227.4b | 245.6b |
Cost of goods sold | (71.5b) | (92.6b) | (102.4b) | (105.3b) |
Gross profit | 93.9b | 103.9b | 129.1b | 144.8b |
R&D expense | (6.7b) | (8.7b) | (7.4b) |
| INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 41.8b | 46.7b | 51.8b | 53.6b | 55.2b | 58.0b | 58.4b | 63.8b | 63.5b | 56.9b | 58.9b | 59.9b |
Cost of goods sold | (19.1b) | (20.4b) | (23.9b) | (23.0b) | (23.7b) | (25.6b) | (24.1b) | (25.2b) | (25.7b) | (23.7b) | (25.1b) | (27.4b) |
Gross profit | 23.9b | 27.3b | 28.9b | 31.6b | 32.5b | 33.5b | 36.1b | 40.1b | 38.7b | 34.2b | 35.3b | 33.0b |
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 12.6b | 19.6b | 28.4b | 54.7b |
Accounts Receivable | 30.8b | 34.1b | 43.2b | 35.0b |
Prepaid Expenses | 3.2b | 2.3b | 5.9b | 4.1b |
Inventories | 58.6b | 72.5b | 77.0b | 90.3b |
| INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 17.8b | 21.3b | 34.8b | 45.0b | ||||||||
Accounts Receivable | 32.0b | 41.6b | 38.1b | 39.3b | ||||||||
Prepaid Expenses | 204.8m | 1.8b | ||||||||||
Inventories | 68.2b | 75.9b | 88.2b | 84.7b |
| INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | 32.4b | 30.9b | 37.4b | 73.4b |
Depreciation and Amortization | 5.6b | 6.7b | 8.7b | 9.4b |
Inventories | (14.1b) | (8.9b) | (5.3b) | (15.9b) |
Accounts Payable | 4.0b | (5.0b) | 3.0b | 1.3b |
| INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 17.3b | 22.8b | 19.9b | |||||||||
Depreciation and Amortization | 4.8b | 5.1b | 5.7b | |||||||||
Inventories | (3.5b) | (11.4b) | 6.1b | |||||||||
Accounts Payable | 2.6b | 3.3b | (5.6b) |
| INR | FY, 2018 |
|---|---|
Revenue/Employee | 11.6m |
Aurobindo Pharma Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Sandoz | September 07, 2018 | $900 m |
Aurobindo Pharma Revenue Breakdown
Aurobindo Pharma revenue breakdown by business segment: 100.0% from MANUFACTURING GENERIC PHARMACEUTICALS AND ACTIVE PHARMACEUTICAL INGREDIENTS
Aurobindo Pharma Cybersecurity Score
Aurobindo Pharma Environment, Social & Governance (ESG) Ratings
Aurobindo Pharma Online and Social Media Presence
Aurobindo Pharma's Trends
Aurobindo Pharma News and Updates
SBI, Infosys, Aurobindo Pharma And More - Top Stock Picks For May: KRChoksey
Aurobindo Pharma Acquires Veritaz's Formulations Business For Rs 171 Crore
Aurobindo Pharma Shares Gain On Cronus Deal Termination
Aurobindo Pharma - Details On 483 Issued By U.S. FDA Towards Unit-I: Prabhudas Lilladher
Aurobindo Pharma Q1 Review - Pricing Pressure Drags Profitability: Motilal Oswal
Aurobindo Pharma Q1 Results: Profit Falls Missing Estimates As U.S. Revenue Contracts
Aurobindo Pharma Frequently Asked Questions
When was Aurobindo Pharma founded?
Aurobindo Pharma was founded in 1986.
Who are Aurobindo Pharma key executives?
Aurobindo Pharma's key executives are M. Sivakumaran, K. Ragunathan and M. Madan Mohan Reddy.
How many employees does Aurobindo Pharma have?
Aurobindo Pharma has 18,469 employees.
What is Aurobindo Pharma revenue?
Latest Aurobindo Pharma annual revenue is ₹245.6 b.
What is Aurobindo Pharma revenue per employee?
Latest Aurobindo Pharma revenue per employee is ₹13.3 m.
Who are Aurobindo Pharma competitors?
Competitors of Aurobindo Pharma include Siegfried Holding, Laboratorios Bago and Libbs Farmaceutica.
Where is Aurobindo Pharma headquarters?
Aurobindo Pharma headquarters is located at Hitech City Rd, Hyderabad.
Where are Aurobindo Pharma offices?
Aurobindo Pharma has offices in Hyderabad and South Brunswick Township.
How many offices does Aurobindo Pharma have?
Aurobindo Pharma has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies